Psychedelic Science 2023 Announces Title Sponsor Psygen Industries Ltd.
May 23th, 2022
Today, Psychedelic Science 2023, hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced that Psygen Industries Ltd. (Psygen) has joined the event as the first Title Sponsor.
With an expected 10,000 attendees, Psychedelic Science 2023 will be the world’s largest gathering of the psychedelic ecosystem, taking place June 17-25, 2023 in Denver, Colorado. The groundbreaking event will feature three days of panels, workshops, and lectures from leaders and visionaries from psychedelic research, education, policy, business, culture, and communities. Conference tracks will be complemented by pre- and post-conference workshops; an exhibit hall; and a marketplace featuring artists, musicians, and other vendors from around the world.
“Psygen is honoured to sponsor the MAPS Psychedelic Science 2023 conference. This event is an excellent opportunity to invest in the ecosystem that will carry psychedelic medicines forward” said Danny Motyka, CEO of Psygen. “Education, collaboration, and community are key attributes for successful implementation of psychedelic assisted therapies — this event ticks all those boxes. We look forward to co-creating a unique and impactful conference experience. See you at the immersive Psygen booth!”
Attendees will include MAPS members and donors, researchers, students, clinicians, advocates, therapists, political leaders, entrepreneurs, executives, investors, psychedelic enthusiasts, and those who may benefit from MAPS’ decades of research and advocacy.
Psygen is a Canadian-based manufacturer licensed to produce GMP restricted drug substances, including MDMA, psilocybin, and LSD. The team has harnessed more than 50 years of combined experience synthesizing psychedelics to provide contract development and manufacturing services and a catalogue of active pharmaceutical Ingredients (APIs) for clinicians, researchers, and drug development companies. Psygen’s APIs have been utilized in clinical trials and in several countries around the world. Psygen aspires to be the world’s preferred supplier of GMP psychedelic APIs.
The team at Psygen is inspired by a duty to provide these medicines and to ensure their transformative potential is better understood and accessible to the industry. Psygen values generosity, non-exclusivity, and access to safe, cost-effective medicines. Psygen is also focused on developing technology to scale commercial production methods that are environmentally sustainable.
More information about Psygen can be found at psygen.ca.
About Momentum Events
Founded in 2012, Momentum Events proudly serves our clients and produces events that attract the best and brightest minds who come together to share their knowledge, connect with the individuals that matter most and enjoy valuable experiences online or in real life. Whether we’re developing cutting edge conferences for the markets we serve, or producing a partner’s next event, Momentum leverages our best in class technology platforms, an assortment of virtual and live event third-party provider relationships, and the meticulous nature of our event planning mindset to deliver true, sustainable value for all stakeholders. www.momentumevents.com
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since MAPS was founded, philanthropic donors and grantors have given more than $130 million for psychedelic and marijuana research and education. MAPS has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.